Adaptive stereotactic radiosurgery for cerebral metastases of non-small cell lung cancer: a retrospective study

INTRODUCTION: Non-small cell lung cancer (NSCLC) is a common cause of brain metastases (BM). Adaptive stereotactic radiosurgery (ASRS) may be a useful option in the treatment of patients with large unresectable brain metastases (BM), but to date there are only a limited number of studies evaluating the effectiveness of this method.

OBJECTIVE: To analyze the effectiveness of ASRS in patients with large BM NSCLC not subject to surgical resection.

MATERIAL AND METHODS: We retrospectively analyzed data from 37 patients suffering from NSCLC with 45 large (>2 cm in diameter, volume >4 cm3) unresectable BM treated with the Gamma Knife Perfexion model using two- and three-fraction ASRS. Of these, 14 foci (31.1%) were metastases of squamous cell lung cancer, 31 (68.9%) were metastases of adenocarcinoma. The median volume of lesions treated with ASRS was 9.8 (range 4.6–30.6 cm3). The dynamics of volume changes between fractions and the cumulative incidence of local relapses (CILR) were studied, and ROC analysis was performed for the tumor volume parameter. Intracranial progression-free survival (iPFS) and overall survival (OS) were assessed. Statistics: To establish statistical significance of differences for related variables, the Wilcoxon test for pairwise comparisons and the Friedman test for three or more groups were used. The Kaplan-Meier method was used to calculate local control, PFS, and OS rates. The log-rank test was used to compare survival data in two groups.

RESULTS: The median follow-up period was 19.4 months. With two-fraction ASRS, the median volume of metastasis decreased by 28.6% by the second session, with three-fraction — by 40.0% by the third session. The 1-year and 2-year CILR rates were 8.6±6.1%, respectively; 26.1±12.3%. In ROC analysis, the area under the curve (AUC) for tumor volume was 0.80 (95% CI 0.6– 1.0) with an optimal cutoff of 18.5 cm3. The differences in CILR between the groups with metastasis volume <18.5 cm3 and ≥18.5 cm3 were statistically significant (p<0.001). Median iPFS was 8.3 (95% CI 5.9–10.7) months, 1-year iPFS was 33.5±8.1%;2-year — 7.8±5.2%. Median OS was 13.2 (95% CI 9.0–17.4) months; 1-year OS — 52.9±8.7%, 2-year — 22.4±8.8%.

DISCUSSION: Using two- and three-fraction ASRS, we delivered doses to large BM sufficient for a high level of local control with an acceptable risk of neurotoxicity: 1-year local control was 91.4%; 2-year — 73.9%; the incidence of radionecrosis is 8.5%. A statistically significant effect of lesion volume ≥18.5 cm3 on the risk of local recurrence was found. The iPFS and OS indicators after ASRS can be considered satisfactory for this group of patients.

CONCLUSION: ASRS is an effective and perhaps optimal strategy for the treatment of large unresectable BM in patients with NSCLC, but comparison with other modern radiotherapy modalities such as stereotactic hypofractionated radiotherapy and WBRT with simultaneous integrated boost is needed.

1. Waqar S.N., Samson P.P., Robinson C.G. et al. Non-small-cell lung cancer with brain metastasis at presentation // Clin. Lung. Cancer. 2018. Vol. 19, No. 4. P. 373– 379. doi: 10.1016/j.cllc.2018.01.007.

2. Solomon B.J., Bauer T.M., Ignatius Ou S.H. et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-smallcell lung cancer from the phase III CROWN study // J. Clin. Oncol. 2022. Vol. 40, No. 31. P. 3593–3602. doi: 10.1200/JCO.21.02278.

3. Vogelbaum M.A., Brown P.D., Messersmith H. et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline // J. Clin. Oncol. 2022. Vol. 40, No. 5. P. 492– 516. doi: 10.1200/JCO.21.02314.

4. Nadal E., Rodríguez-Abreu D., Simó M. et al. Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous nonsmall-sell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05) // J. Clin. Oncol. 2023. Vol. 41, No. 28. P. 4478–4485. doi: 10.1200/JCO.22.02561.

5. Kocher M., Soffietti R., Abacioglu U. et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study // J. Clin. Oncol. 2011. Vol. 29, No. 2. P.134–141. doi: 10.1200/JCO.2010.30.1655.

6. Sas-Korczynska B., Rucinska M. et al. WBRT for brain metastases from non-small cell lung cancer: for whom and when? — Contemporary point of view // J. Thorac. Dis. 2021. Vol. 13, No. 5. P. 3246–3257. doi: 10.21037/jtd-2019-rbmlc-06.

7. Chang E.L., Wefel J.S., Hess K.R. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial // Lancet Oncol. 2009. Vol. 10, No. 11. P.1037–1044. doi: 10.1016/S1470-2045(09)70263-3.

8. Shaw E., Scott C., Souhami L. et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05 // Int. J. Radiat. Oncol. Biol. Phys. 2000. Vol. 47, No. 2. P. 291–298. doi: 10.1016/s0360-3016(99)00507-6.

9. Higuchi Y., Serizawa T., Nagano O. et al. Three-staged stereotactic radiotherapy without whole brain irradiation for large metastatic brain tumors // Int. J. Radiat. Oncol. Biol. Phys. 2009. Vol. 74, No. 5. P. 1543–1538. doi: 10.1016/j.ijrobp.2008.10.035.

10. Yomo S., Hayashi M., Nicholson C. A prospective pilot study of two-session Gamma Knife surgery for large metastatic brain tumors // J. Neurooncol. 2012. Vol. 109, No. 1. P. 159–165. doi: 10.1007/s11060-012-0882-8.

11. Osinov I.K., Golanov A.V., Banov S.M. et al. Staged radiosurgery in the managment of patients with brain metastases // Russian journal of neurosurgery. 2021. Vol. 23, No. 1. P. 26–37 (In Russ.) doi: 10.17650/1683-3295-2021-23-1-26-37.

12. Sperduto P.W., De B., Li J. et al. Graded prognostic assessment (GPA) for patients with lung cancer and brain metastases: initial report of the small cell lung cancer GPA and update of the non-small cell lung cancer GPA including the effect of programmed death ligand 1 and other prognostic factors // Int. J. Radiat. Oncol. Biol. Phys. 2022. Vol. 114, No. 1. Р. 60–74. doi: 10.1016/j.ijrobp.2022.03.020.

13. Korytko T., Radivoyevitch T., Colussi V. et al. 12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors // Int. J. Radiat. Oncol. Biol. Phys. 2006. Vol. 64, No. 2. P. 419–424. doi: 10.1016/j.ijrobp.2005.07.980.

14. Cox J.D., Stetz J., Pajak T.F. et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) // Int. J. Radiat. Oncol. Biol. Phys. 1995. Vol. 31, No. 5. P. 1341–1346. doi: 10.1016/0360-3016(95)00060-C.

15. Shaw E., Scott C., Souhami L. et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05 // Int. J. Radiat. Oncol. Biol. Phys. 2000. Vol. 47, No. 2. P. 291–298. doi: 10.1016/s0360-3016(99)00507-6.

16. Ito D., Aoyagi K., Nagano O. et al. Comparison of two-stage Gamma Knife radiosurgery outcomes for large brain metastases among primary cancers // J. Neurooncol. 2020. Vol. 147, No. 1. P. 237–246. doi: 10.1007/s11060-020-03421-y.

17. Terry F., Merenzon M., Daggubati L. et al. Two-stage radiosurgery for large brain metastases: a systematic review and meta-analysis of clinical outcomes // Neurosurg Focus. 2023. Vol. 55, No. 2. E5.

18. Serizawa T., Higuchi Y., Yamamoto M. et al. Comparison of treatment results between 3- and 2-stage Gamma Knife radiosurgery for large brain metastases: a retrospective multi-institutional study // J. Neurosurg. 2018. Vol. 131, No. 1. P. 227–237. doi: 10.3171/2018.4.JNS172596.

19. Medvedeva K.E., Baulin A.A., Lepilina O.G. et al. Two-stage Gamma Knife radiosurgery for brain metastases. Radiation and Risk, 2022, Vol. 3, No. 1, рр. 136–149 (In Russ.). doi: 10.21870/0131-3878-2022-31-1-136-149.

20. Cho A., Medvedeva K.E., Kranawetter B. et al. How to dose-stage large or high-risk brain metastases: an alternative two-fraction radiosurgical treatment approach // J. Neurosurg. 2022. Vol. 137. P. 1666–1675. doi: 10.3171/2022.2.JNS212440.

21. Ilyalov S.R., Parshunina A.M., Kvashnin K.M. Staged radiosurgery of large brain metastasis with mass effect and brain dislocation: case report. Russian Journal of Neurosurgery, 2022, Vol. 24, рр. 66–71 (In Russ.) doi: 10.17650/1683‐3295‐2022‐24‐2‐66‐71.